DNA sequencing

Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
Health, Genetics, Medical device, Sanger, NGS, DNA, DNA sequencing, Update, Oil, Pharmaceutical industry

The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
  • The publisher's Medical Devices sector report, "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update' provides comprehensive information about the Next Generation Sequencing (NGS) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    The report enables you to:
    In-depth analysis of the product's current stage of development, territory and estimated launch date

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Retrieved on: 
Tuesday, November 15, 2022
New England Biolabs, Growth, Technology, Board, Hepatitis B, Intention, Environment, Therapy, Forward-looking statement, Degenerative disease, View, Company, NGS, Herpes simplex, Terminology, Research, Multimedia, COVID-19, Nature, Roche Diagnostics, Commercial Operating System (COS), DNA sequencing, Diagnosis, Monkeypox, Vaccine, Malaria

LONDON, Nov. 15, 2022 /PRNewswire/ --Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.

Key Points: 
  • LONDON, Nov. 15, 2022 /PRNewswire/ --Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.
  • "We are thrilled to welcome Richard to our team," said James Foster, Chairman of the Board and Chief Executive Officer of Virax Biolabs.
  • As the Vice President of In Vitro Diagnostic Sales, Mr. Pallin will lead Virax's commercial team and lead the execution of the Company's go-to-market strategy.
  • Prior to joining Virax, Mr. Pallin was the Vice President of Global Commercial Operations of Omixon, Inc., a global transplantation diagnostic company dedicated to transitioning the human leukocyte antigen community to Next Generation Sequencing (NGS) technologies.

Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

Retrieved on: 
Thursday, November 3, 2022
Senior, Colon, Precision, Clinical trial, Association, Ion semiconductor sequencing, Prevalence, Medicine, Gene, Neoplasm, Association for Molecular Pathology v. Myriad Genetics, Inc., Therapy, Thermo Fisher Scientific, DNA sequencing, Doctor of Philosophy, Tissue, Mutation, Method, Patient, Cancer, Prostate, CRO, CNV, Biomarker, Breast, Melanoma, Precision medicine, Lung, NGS, Database, Medical imaging, Pharmaceutical industry

Collaborating with Thermo Fisher, Precision for Medicine performed a mass screening of samples from Precision's extensive biorepository for key mutations across 11 cancer indications, including lung, breast, colon, prostate, melanoma, thyroid, bladder and others.

Key Points: 
  • Collaborating with Thermo Fisher, Precision for Medicine performed a mass screening of samples from Precision's extensive biorepository for key mutations across 11 cancer indications, including lung, breast, colon, prostate, melanoma, thyroid, bladder and others.
  • Accelerating the validation and regulatory approval process will ultimately lead to faster development of personalized (targeted) therapeutics and diagnostics for patients."
  • Ongoing work includes using these tumors to support cross-site validation of novel diagnostics for regulatory approval."
  • Precision for Medicine is part of Precision Medicine Group with over 3000 people in 40 locations in the U.S., Canada, and Europe.

Biochips Global Market Report 2022: Increase in Adoption of Next-Generation Sequencing Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Pharmaceutical, Health, Biometrics, Growth, DNA, Hospital, Midsayap Diagnostic Center and Hospital, Cancer, Gene expression profiling, Industry, Abbott, Thermo Fisher Scientific, CAGR, Technology, Traumatic brain injury, Adoption, Investment, USD, Union, Investor, Genome, DNA sequencing, Research, Academy, NGS, TBI, Biotechnology, Drug discovery, CE marking, Pharmaceutical industry, Fine chemical

The global biochips market size is expected to reach USD 25.92 billion by 2030, registering a CAGR of 13.35% during the forecast period.

Key Points: 
  • The global biochips market size is expected to reach USD 25.92 billion by 2030, registering a CAGR of 13.35% during the forecast period.
  • The rising requirement for drug discovery and development coupled with the adoption of personalized medicine is likely to favor the industry's growth.
  • Furthermore, the rise in the implementation of next-generation sequencing by biotechnology companies around the globe is pushing product demand.
  • The chip is an advancement in the Next-Generation Sequencing (NGS) technology that makes massively parallel sequencing cost-effective for every lab.

$7.8 Billion Worldwide Gene Expression Analysis Industry to 2027 - Featuring Agilent Technologies, GE Healthcare and Illumina Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Health, Genetics, R, NGS, Toxicology, Therapy, Conditional sentence, Drug development, Prevalence, GEA, Cancer, Growth, RNA, Adoption, List of life sciences, Pacific Biosciences, Technology, RNA splicing, Protein, Industry, DNA sequencing, Research, COVID-19, Tuberculosis, Gene, Vaccine, Potash

Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems.

Key Points: 
  • Gene expression analysis (GEA) is the method of extracting data from a gene to investigate the behaviour of biological systems.
  • The data obtained from this analysis is used for the production of proteins, Ribonucleic Acid (RNA) and various microbiological products.
  • What has been the impact of COVID-19 on the global gene expression analysis market?
  • What is the structure of the global gene expression analysis market and who are the key players?

Meeting the Increasing Manufacturing Demands of the Rapidly Growing Cell and Gene Therapy and Vaccine Markets, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Friday, October 28, 2022
Food, Plasmid, Engineering, VP, DNA, Doctor of Philosophy, DNA sequencing, CGMP, Rapidly progressive glomerulonephritis, Industry, Process, Gene therapy, Guideline, AAV, Program management, Associate Director of National Intelligence and Chief Information Officer, AstraZeneca, Vaccine

TORONTO, Ontario, Oct. 28, 2022 /PRNewswire-PRWeb/ -- Join this webinar to discuss the growing cell and gene therapy and vaccine markets, the resulting critical bottlenecks in plasmid (pDNA) production, and how these bottlenecks are being addressed by collaborations and partnerships between some of the key contributors to the biomanufacturing supply chain.

Key Points: 
  • In this free webinar, learn about the rapidly growing cell and gene therapy and vaccine markets.
  • Attendees will learn about full-scale engineering and process validation capabilities enabling cGMP production, completion of clinical trials, and approved therapy commercialization.
  • Register to learn about meeting the increasing manufacturing demands of the rapidly growing cell and gene therapy and vaccine markets.
  • For more information, or to register for this event, visit Meeting the Increasing Manufacturing Demands of the Rapidly Growing Cell and Gene Therapy and Vaccine Markets .

EQS-News: SYNLAB AG: SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME

Retrieved on: 
Friday, October 28, 2022
NGS, DNA, DNA sequencing, Bacteria, Conditional sentence, Patient, Technology, Synlab Group, Quality of life, Archaea, Genetics, Health, Fungus, Antibiotics, Dietary supplement

Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microbas leading researchers in the field of microbiome analysis.

Key Points: 
  • Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microbas leading researchers in the field of microbiome analysis.
  • The combination of leading-edge comprehensive metagenomic sequencing and evidence-based reporting provides precise imaging of the gut microbiome.
  • myBIOME provides a comprehensive analysis of the composition of an individuals gut microbiome and its functional potential to deliver personalized treatment or nutrition recommendations.
  • Consumers and healthcare professionals alike benefit from the comprehensive gut microbiome analysis that myBIOME provides to detect the cause of a broad range of health complaints.

SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME

Retrieved on: 
Friday, October 28, 2022
Biotechnology, General Health, Health, Pharmaceutical, Oncology, NGS, Acquisition, Switzerland, DNA, DNA sequencing, Group, Disease, Hospital, MAP, Bacteria, Conditional sentence, Patient, Synlab Group, Quality of life, Archaea, ASX, Genetics, Health, Fungus, Dietary supplement, Medical device, Antibiotics

SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.

Key Points: 
  • SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.
  • myBIOME is the most complete and accurate metagenomic sequencing test available on the market today, allowing for a comprehensive, highly differentiated and actionable analysis of an individuals gut microbiome.
  • Applying game-changing metagenomic technology developed by Microba, myBIOME detects all types of microorganisms (bacteria, archaea, fungi, protists), identifies the exact species and characterises new species.
  • Microba Life Sciences (ASX: MAP) is a precision microbiome company driven to improve human health.

G42 Healthcare Strengthens Clinical Genomics Offering with Saphetor’s VarSome Bioinformatics Platform, Strengthens UAE’s Position as a Global Leader in Healthcare Innovation

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Technology, Other Health, Health, Biometrics, Oncology, Other Technology, Medical Devices, Apps, Applications, Software, Internet, API, Health care, Life, Population, Diagnosis, Vaccine, Lists of diseases, Genomics, Volunteering, Hospital, Research, Publication, Partnership, Cancer, Technology, DNA sequencing, Disorder, NGS, Health, AI, Founder, CEO, IROS, International Grape Genome Program, Omics, Next Generation, Classification, COVID-19, Solution, Medical device, Medical imaging, Pharmaceutical industry, G42

The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies, with the shortest turnaround time.

Key Points: 
  • The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing technologies, with the shortest turnaround time.
  • This collaboration also enables clinical genomics, at scale, as a service, using G42 Healthcares 3 genomic sequencing platforms offering both long and short read capabilities.
  • The collaboration will fortify G42 Healthcares clinical genomics solutions by leveraging the VarSome suite of bioinformatics tools to deliver valuable data insights and improved outcomes.
  • VarSome Premium and VarSome Clinical are professional editions of VarSome with powerful functionality and further sophisticated data-mining and analysis tools.

Nextech AR Announces Record $6.7 Million 3D Model Purchase Order From a NASDAQ 100 Technology Company

Retrieved on: 
Tuesday, October 18, 2022
Metaverse, LinkedIn, FSE, N29, 2D, 170, Augmented reality, Growth, Robotics, E-commerce, YouTube, AR, NASDAQ, 3D, Contract, Social media, Twitter, Instagram, Technology, ROI, Social, Blockchain, Company, Industry, AI, CSE, NTAR, DNA sequencing, GLOBE, Artificial intelligence, Iveco Bus, Calendar, Nex Entertainment, Television, 3D printing, Facebook

("Nextech" or the "Company") ( OTCQB: NEXCF ) ( CSE: NTAR ) (FSE: N29), a Metaverse Company and leading provider of augmented reality ("AR") experience technologies, wayfinding technologies and 3D model services is pleased to announce it has received its single largest purchaser order to date of $6.7 million from a NASDAQ 100 technology company.

Key Points: 
  • ("Nextech" or the "Company") ( OTCQB: NEXCF ) ( CSE: NTAR ) (FSE: N29), a Metaverse Company and leading provider of augmented reality ("AR") experience technologies, wayfinding technologies and 3D model services is pleased to announce it has received its single largest purchaser order to date of $6.7 million from a NASDAQ 100 technology company.
  • With the previously announced $700,000 3D model order to be delivered in Q4, 2022 the total new orders recently announced equals $7.4 million.
  • These new 3D model orders set the stage for record growth in its 3D modeling business for the foreseeable future.
  • While $6.7 million is the most substantial 3D modeling order Nextech AR has received to date, the Company is still in negotiations for additional significant 3D modeling contracts from large enterprise customers, which it expects to announce shortly.